XML 115 R80.htm IDEA: XBRL DOCUMENT
v3.25.2

Net Loss Per Share Attributable to Common Stockholders - Schedule of Diluted Net Loss Attributable to Nuvve common stockholders (Details) - shares | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 20,235,121 | 1,544,215 | 20,235,121 | 1,543,293
Stock options issued and outstanding |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 6,649 | 7,285 | 6,649 | 6,876
Nonvested restricted stock issued and outstanding |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 0 | 518 | 0 | 4
Public warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 7,188 | 7,188 | 7,188 | 7,188
Private warrants - February 2020 |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 341 | 341 | 341 | 341
PIPE warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 3,384 | 3,384 | 3,384 | 3,384
Stonepeak and Evolve warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 0 | 15,000 | 0 | 15,000
Stonepeak and Evolve options |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 0 | 12,500 | 0 | 12,500
2022 July Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 10,000 | 10,000 | 10,000 | 10,000
Underwriter Warrants - February 2024 offering |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 25,500 | 48,000 | 25,500 | 48,000
2024 February Institutional/Accredited Investor Warrants - series A |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 480,000 | 480,000 | 480,000 | 480,000
2024 February Institutional/Accredited Investor Warrants - series B |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 0 | 480,000 | 0 | 480,000
2024 February Institutional/Accredited Investor Warrants - series C |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 30,000 | 480,000 | 30,000 | 480,000
2024 October Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 375,684 | 0 | 375,684 | 0
2024 December Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 277,780 | 0 | 277,780 | 0
2025 March Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 1,492,722 | 0 | 1,492,722 | 0
2025 April Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 1,183,991 | 0 | 1,183,991 | 0
2025 May Institutional/Accredited Investor Warrants |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 5,341,879 | 0 | 5,341,879 | 0
Warrants - May 7, 2025 - 1st Tranche |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 9,000,000 | 0 | 9,000,000 | 0
Warrants - May 7, 2025 - 2nd Tranche |  |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |  |  |  |
Antidilutive securities excluded from the computation of earnings per share (in shares) | 2,000,004 | 0 | 2,000,004 | 0

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_StockOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_NonvestedRestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_PublicWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_PrivateWarrantsFebruary2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_PIPEWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_StonepeakAndEvolveWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_StonepeakAndEvolveOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_July2022InstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_UnderwriterWarrantsFebruary2024OfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_February2024InstitutionalAccreditedInvestorWarrantsSeriesAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_February2024InstitutionalAccreditedInvestorWarrantsSeriesBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_February2024InstitutionalAccreditedInvestorWarrantsSeriesCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_October2024InstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_A2024DecemberInstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_March2025InstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_A2025AprilInstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_A2025MayInstitutionalAccreditedInvestorWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_May2025ConsultingWarrants1stTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nvve_May2025ConsultingWarrants2ndTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |